Serum autotaxin is not a useful biomarker for ovarian cancer

Kazuhiro Nakamura, Koji Igarashi, Ryunosuke Ohkawa, Hiromitsu Yokota, Akiko Masuda, Shunsuke Nakagawa, Tetsu Yano, Hitoshi Ikeda, Junken Aoki, Yutaka Yatomi

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


Autotaxin (ATX) is a glycoprotein that was first identified in the conditioned medium of human melanoma cells as an autocrine motility factor. It possesses lysophospholipase D activity, producing the bioactive lipid mediator lysophosphatidic acid (LPA) from lysophosphatidylcholine. Enhanced expression of ATX mRNA has been reported in various cancer cells and tissues, and it has been speculated that ATX overexpression in cancer cells may be associated with aberrant LPA production. LPA and ATX have been implicated in cancer progression and metastasis, and ovarian cancer is a representative example. In the present study, we measured the serum ATX antigen levels in patients with ovarian cancer and evaluated the usefulness of this parameter for clinical laboratory testing. The serum ATX antigen levels were not increased in ovarian cancer patients as compared with the levels in healthy subjects, and the serum ATX may not be useful as a biomarker for ovarian cancer.

Original languageEnglish
Pages (from-to)927-930
Number of pages4
Issue number9
Publication statusPublished - 2012 Sept


  • Autotaxin
  • Clinical laboratory testing
  • Immunoenzymetric assay
  • Lysophosphatidic acids
  • Ovarian cancer
  • Tumor marker

ASJC Scopus subject areas

  • Biochemistry
  • Organic Chemistry
  • Cell Biology


Dive into the research topics of 'Serum autotaxin is not a useful biomarker for ovarian cancer'. Together they form a unique fingerprint.

Cite this